UGP2 and metabolic dysfunction-associated steatotic liver disease: The mechanism through which SCP could play a therapeutic role in NAFLD was confirmed by detecting the expression of the key targets in these metabolic pathways, including UGP2, UGDH, ACC, and FAS proteins.